<bill session="117" type="s" number="2529" updated="2023-01-01T23:42:30Z">
  <state datetime="2021-07-29">REFERRED</state>
  <status>
    <introduced datetime="2021-07-29"/>
  </status>
  <introduced datetime="2021-07-29"/>
  <titles>
    <title type="official" as="introduced">A bill to amend the Internal Revenue Code of 1986 to provide for advance refunds of certain net operating losses and research expenditures relating to COVID-19, and for other purposes.</title>
    <title type="display">IGNITE American Innovation Act</title>
    <title type="short" as="introduced">IGNITE American Innovation Act</title>
    <title type="short" as="introduced">Innovation and Growth Now by Investing in Tomorrow&#226;&#8364;&#8482;s Enterprises Act</title>
  </titles>
  <sponsor bioguide_id="M000639"/>
  <cosponsors/>
  <actions>
    <action datetime="2021-07-29">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-07-29" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="3623" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Taxation"/>
    <term name="Business expenses"/>
    <term name="Cardiovascular and respiratory health"/>
    <term name="Corporate finance and management"/>
    <term name="Disability assistance"/>
    <term name="Drug therapy"/>
    <term name="Emergency medical services and trauma care"/>
    <term name="Health promotion and preventive care"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Income tax credits"/>
    <term name="Income tax deductions"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Medical research"/>
    <term name="Medical tests and diagnostic methods"/>
    <term name="Prescription drugs"/>
    <term name="Research and development"/>
  </subjects>
  <amendments/>
  <summary date="2021-11-08T16:46:02Z" status="Introduced in Senate">Innovation and Growth Now by Investing in Tomorrow's Enterprises Act or the IGNITE American Innovation Act

This bill allows certain C corporation taxpayers to elect an increased advance refund of net operating loss carryovers attributable to COVID-19 research expenditures in 2020 and 2021. The bill also allows such taxpayers an advance refund of certain other net operating loss carryovers arising during 2015 through 2021.

The bill allows an increased research tax credit for COVID-19 research expenditures paid or incurred on or after February 15, 2020, and before January 1, 2022.</summary>
</bill>
